Alpha Cognition Inc. (ACOGF)
USD 5.73
(N/A%)
USD 5.73
(N/A%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.45 Million USD | -16.9% |
| 2022 | 2.95 Million USD | -77.09% |
| 2021 | 12.88 Million USD | 52.68% |
| 2020 | 8.43 Million USD | 31.9% |
| 2019 | 6.39 Million USD | 2395.42% |
| 2018 | 256.3 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.08 Million USD | -40.05% |
| 2024 Q1 | 3.47 Million USD | 41.63% |
| 2023 Q4 | 2.45 Million USD | 44.3% |
| 2023 FY | 2.45 Million USD | -16.9% |
| 2023 Q3 | 1.69 Million USD | -11.29% |
| 2023 Q2 | 1.91 Million USD | -58.61% |
| 2023 Q1 | 4.62 Million USD | 56.83% |
| 2022 Q4 | 2.95 Million USD | -33.93% |
| 2022 FY | 2.95 Million USD | -77.09% |
| 2022 Q2 | 6.84 Million USD | -35.98% |
| 2022 Q1 | 10.68 Million USD | -17.05% |
| 2022 Q3 | 4.46 Million USD | -34.71% |
| 2021 Q3 | 6.36 Million USD | -1.15% |
| 2021 Q2 | 6.43 Million USD | -21.75% |
| 2021 Q1 | 8.22 Million USD | 551.9% |
| 2021 Q4 | 12.88 Million USD | 102.35% |
| 2021 FY | 12.88 Million USD | 52.68% |
| 2020 Q3 | 8.22 Million USD | 0.0% |
| 2020 FY | 8.43 Million USD | 31.9% |
| 2020 Q4 | 1.26 Million CAD | -84.66% |
| 2019 Q4 | 6.39 Million USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | 665.62 Thousand USD | 2395.42% |
| 2018 FY | 256.3 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -106054.545% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -25.226% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 76.765% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -344.137% |
| Rebus Holdings, Inc. | 5000.00 USD | -48943.4% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.117% |
| Qrons Inc. | 420.00 USD | -583750.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -218.198% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 91.225% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -410.277% |
| Skye Bioscience, Inc. | 11.94 Million USD | 79.463% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 93.688% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 66.035% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -3111.58% |
| SQZ Biotechnologies Company | 107.18 Million USD | 97.712% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -71.237% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -3288.613% |
| Mesoblast Limited | 667.9 Million USD | 99.633% |
| Marizyme, Inc. | 22.01 Million USD | 88.861% |
| Genus plc | 1.02 Billion USD | 99.762% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -80.525% |
| Pharming Group N.V. | 462.85 Million USD | 99.47% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 25.984% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -391.378% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -291.096% |
| ContraFect Corporation | 20.67 Million USD | 88.142% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -528.172% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -541.632% |
| IMV Inc. | 31.33 Million USD | 92.174% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 40.855% |
| MultiCell Technologies, Inc. | 126.22 USD | -1942674.521% |
| ONE Bio Corp. | 70.08 Million USD | 96.501% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -160.955% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.092% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -468.008% |
| Q BioMed Inc. | 3.51 Million USD | 30.247% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 93.029% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -838.533% |
| Biomind Labs Inc. | 73.81 Thousand USD | -3221.868% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.451% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -69.25% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 91.83% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 10.711% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -256.687% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 5.802% |
| GB Sciences, Inc. | 103.44 Thousand USD | -2270.575% |
| HST Global, Inc. | 1526.00 USD | -160592.661% |
| CSL Limited | 38.02 Billion USD | 99.994% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -148.204% |
| Halberd Corporation | 10.13 Thousand USD | -24104.619% |
| Enzolytics Inc. | 361.7 Million USD | 99.322% |
| Agentix Corp. | 261.39 Thousand USD | -838.12% |
| Resverlogix Corp. | 8.11 Million USD | 69.782% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -30.582% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.946% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 94.859% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -283.358% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -10664.102% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 72.599% |
| AVAX Technologies, Inc. | 7.37 Million USD | 66.76% |
| Zenith Capital Corp. | 7410.00 USD | -32992.713% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.928% |
| Ember Therapeutics, Inc. | 184.00 USD | -1332601.087% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -662.003% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -838.22% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -164.254% |
| Kadimastem Ltd | 2.3 Million USD | -6.427% |
| Helix BioMedix, Inc. | 3.02 Million USD | 18.939% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 95.347% |
| BioStem Technologies, Inc. | 14.56 Million USD | 83.159% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -4194.97% |
| LadRx Corporation | 2.3 Million USD | -6.252% |
| Cell Source, Inc. | 195.17 Thousand USD | -1156.421% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -593.454% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -593.454% |
| NovAccess Global Inc. | 62.24 Thousand USD | -3839.355% |
| Affymax, Inc. | 7.44 Million USD | 67.054% |
| Itoco Inc. | 1.4 Million USD | -75.146% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -2463.503% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -2213.368% |
| Mobile Lads Corp. | 52.00 USD | -4715611.538% |
| CytoDyn Inc. | 11.13 Million USD | 77.98% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1615.14% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -13614.597% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -536.149% |
| SYBLEU INC | 330.46 Thousand USD | -642.029% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -498.935% |
| International Stem Cell Corporation | 5.39 Million USD | 54.505% |
| Bioxytran, Inc. | 137.63 Thousand USD | -1681.608% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 83.654% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 85.209% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -3004.013% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -183.594% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 67.378% |
| Neutra Corp. | 2851.00 USD | -85910.873% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 92.433% |
| PureTech Health plc | 693.97 Million USD | 99.647% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 69.618% |
| IXICO plc | 15.84 Million USD | 84.523% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 70.392% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.627% |
| CSL Limited | 38.02 Billion USD | 99.994% |
| Cellectis S.A. | 333.99 Million USD | 99.266% |